킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

European Congress of Rheumatology 2021 (EULAR 2021) VIRTUAL

02 June - 05 June, 2021, France

Apremilast improves Behcet’s syndrome-related oral ulcers in both sexes

2021-09-10

The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.
Certain rheuma therapies tied to poorer COVID-19 outcomes, impaired vaccine response

2021-09-10

Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
COSMOS: Guselkumab improves response rates in active psoriatic arthritis

2021-09-10

Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.
COVID-19 vaccine safe in people with rheumatic diseases

2021-09-10

Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).
Iberdomide confers dermatologic benefit for SLE

2021-09-10

A high dose of the high-affinity cereblon ligand iberdomide delivered beneficial effects on the cutaneous manifestations of systemic lupus erythematosus (SLE), according to a phase II study presented at EULAR 2021.
IVIg therapy gains the upper hand in ProDERM

2021-09-10

Results of the phase III, placebo-controlled ProDERM trial reported at EULAR 2021 showed significant efficacy and acceptable safety for immunoglobulin therapy given intravenously (IVIg) to patients with dermatomyositis – a systemic autoimmune disease marked by progressive proximal muscle weakness and a distinctive skin rash.
KEEPsAKE2 trial reveals potential of risankizumab for psoriatic arthritis

2021-09-10

The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.
Mavrilimumab improves outcomes in nonventilated patients with severe COVID-19, hyperinflammation

2021-09-10

The human monoclonal antibody mavrilimumab reduced the rates of mechanical ventilation and death in nonmechanically ventilated patients with severe COVID-19 pneumonia and systemic hyperinflammation, according to a phase II/III study presented at EULAR 2021.
No increased risk of COVID-19 in patients with RMDs

2021-09-10

There is no evidence so far that patients with rheumatic and musculoskeletal diseases (RMDs) are at an increased risk of COVID-19 or have a worse prognosis, says a rheumatology expert at EULAR 2021.
Secondhand smoke may up risk of RA

2021-09-10

Exposure to secondhand smoke, regardless of whether it is during childhood or adulthood, is associated with an increased risk of developing rheumatoid arthritis (RA) among women — particularly in those who never smoke themselves, according to data from the E3N-EPIC study presented at the EULAR 2021 Congress.
Secukinumab promising for paediatric enthesitis-related arthritis and juvenile psoriatic arthritis

2021-09-10

Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
TNFi treatment in rheumatic disease not a risk for COVID-19 hospitalization

2021-09-10

Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 소현정 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (09:00~18:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2022 KIMS Co., Ltd All Rights Reserved

KIMS APP

KIMS 페이스북

KIMS 트위터